» Articles » PMID: 35295103

An Adverse Outcome Pathway for Decreased Lung Function Focusing on Mechanisms of Impaired Mucociliary Clearance Following Inhalation Exposure

Overview
Journal Front Toxicol
Date 2022 Mar 17
PMID 35295103
Authors
Affiliations
Soon will be listed here.
Abstract

Adverse outcome pathways (AOPs) help to organize available mechanistic information related to an adverse outcome into key events (KEs) spanning all organizational levels of a biological system(s). AOPs, therefore, aid in the biological understanding of a particular pathogenesis and also help with linking exposures to eventual toxic effects. In the regulatory context, knowledge of disease mechanisms can help design testing strategies using methods that can measure or predict KEs relevant to the biological effect of interest. The AOP described here evaluates the major processes known to be involved in regulating efficient mucociliary clearance (MCC) following exposures causing oxidative stress. MCC is a key aspect of the innate immune defense against airborne pathogens and inhaled chemicals and is governed by the concerted action of its functional components, the cilia and airway surface liquid (ASL). The AOP network described here consists of sequences of KEs that culminate in the modulation of ciliary beat frequency and ASL height as well as mucus viscosity and hence, impairment of MCC, which in turn leads to decreased lung function.

Citing Articles

Evaluation of a non-animal toolbox informed by adverse outcome pathways for human inhalation safety.

de Avila R, Muller I, Barlow H, Middleton A, Theiventhran M, Basili D Front Toxicol. 2025; 7:1426132.

PMID: 40061084 PMC: 11885506. DOI: 10.3389/ftox.2025.1426132.


Nanosuspension Innovations: Expanding Horizons in Drug Delivery Techniques.

Jacob S, Kather F, Boddu S, Attimarad M, Nair A Pharmaceutics. 2025; 17(1).

PMID: 39861782 PMC: 11768797. DOI: 10.3390/pharmaceutics17010136.


New approach methodologies (NAMs) for the assessment of cleaning products for respiratory irritation: workshop report.

Haber L, Bradley M, Buerger A, Behrsing H, Burla S, Clapp P Front Toxicol. 2024; 6:1431790.

PMID: 39439531 PMC: 11493779. DOI: 10.3389/ftox.2024.1431790.


Applying new approach methodologies to assess next-generation tobacco and nicotine products.

Thorne D, McHugh D, Simms L, Lee K, Fujimoto H, Moses S Front Toxicol. 2024; 6:1376118.

PMID: 38938663 PMC: 11208635. DOI: 10.3389/ftox.2024.1376118.


Differences in the anatomy and physiology of the human and rat respiratory tracts and impact on toxicological assessments.

Stucki A, Sauer U, Allen D, Kleinstreuer N, Perron M, Yozzo K Regul Toxicol Pharmacol. 2024; 150:105648.

PMID: 38772524 PMC: 11198871. DOI: 10.1016/j.yrtph.2024.105648.


References
1.
Boek W, Keles N, Graamans K, Huizing E . Physiologic and hypertonic saline solutions impair ciliary activity in vitro. Laryngoscope. 1999; 109(3):396-9. DOI: 10.1097/00005537-199903000-00010. View

2.
Derichs N . Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis. Eur Respir Rev. 2013; 22(127):58-65. PMC: 9487424. DOI: 10.1183/09059180.00008412. View

3.
Lai S, Wang Y, Wirtz D, Hanes J . Micro- and macrorheology of mucus. Adv Drug Deliv Rev. 2009; 61(2):86-100. PMC: 2736374. DOI: 10.1016/j.addr.2008.09.012. View

4.
Kilgour E, Rankin N, Ryan S, Pack R . Mucociliary function deteriorates in the clinical range of inspired air temperature and humidity. Intensive Care Med. 2004; 30(7):1491-4. DOI: 10.1007/s00134-004-2235-3. View

5.
Ishikawa S, Ito S . Repeated whole cigarette smoke exposure alters cell differentiation and augments secretion of inflammatory mediators in air-liquid interface three-dimensional co-culture model of human bronchial tissue. Toxicol In Vitro. 2016; 38:170-178. DOI: 10.1016/j.tiv.2016.09.004. View